Why the growth investor may take a look at NASDAQ:TGTX.

In this article we will dive into TG THERAPEUTICS INC (NASDAQ:TGTX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed TG THERAPEUTICS INC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Why NASDAQ:TGTX may be interesting for growth investors.

• TG THERAPEUTICS INC exhibits a strong Return on Equity (ROE) of 53.87%, indicating the company's ability to generate solid returns on shareholder investments. This metric reflects the company's efficient utilization of equity capital and its profitability.
• TG THERAPEUTICS INC has surpassed EPS estimates 3 times in the last 4 quarters, reflecting its strong financial performance and effective management. This trend suggests the company's ability to generate positive earnings surprises and drive shareholder value.
• The 1-year revenue growth of TG THERAPEUTICS INC (1.0K%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
• TG THERAPEUTICS INC has experienced 357.0% q2q revenue growth, indicating a significant sales increase.
• TG THERAPEUTICS INC has shown positive growth in its operating margin over the past year, indicating improved operational efficiency. This growth highlights the company's ability to effectively manage costs and maximize profitability.
• With a favorable trend in its free cash flow (FCF) over the past year, TG THERAPEUTICS INC demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
• The recent financial report of TG THERAPEUTICS INC demonstrates a 112.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• TG THERAPEUTICS INC has seen a 31.92% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
• The recent financial report of TG THERAPEUTICS INC demonstrates a 112.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• accelerating EPS growth for TG THERAPEUTICS INC: the current Q2Q growth of 112.0% exceeds the previous year Q2Q growth of -13.33%.

A complete fundamental analysis of NASDAQ:TGTX

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

TGTX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. TGTX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TGTX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make TGTX a good candidate for growth investing.

Our latest full fundamental report of TGTX contains the most current fundamental analsysis.

More growth stocks can be found in our Lois Navellier screen.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.